Although there have been significant advances in the identification of biomarkers of Alzheimer's disease (AD), comorbidity is a common finding at autopsy and the neuropathologic assessment at autopsy remains the gold standard for diagnosis.
The aims of the Neuropathology Core (Core D) will be: (1) To make neuropathologic diagnoses on all new brain accessions from HASD research participants using standard diagnostic criteria;(2) To perform brain autopsies and to collect, store at -80?C, and distribute formalin-fixed, paraffin-embedded, and frozen brain tissue samples to support HASD Projects and investigators and outside collaborations that enhance HASD research goals;(3) To support Projects 1 and 2 by providing a neuropathologic assessment and quantitative measures of the molecular pathology (beta- amyloidosis, tauopathy, synucleinopathy, and TDP-43 proteinopathy) of cases which come to autopsy. To support the Specific Aims of Project 3 by providing neuropathologic data, quantitative measures of the molecular pathology, and tissue (for mRNA and DNA extraction) relating to cases recruited for the study of genetic variants and their influence on the progression of AD (4) To maintain a computerized neuropathology database (CaTissue) in concert with the Biostatistics Core (Core C) and the Clinical Core (Core B) and the Washington University Neuroscience Blueprint Interdisciplinary Center Core (P30 NS057105). Information stored will include macroscopic images of fresh and fixed brain, demographic data, diagnoses, semi- quantitative morphometric data, neuropathology reports in collaboration with Dr. Perrin, bibliographic information, and data relevant to Core tissue banking activities. If acceptable, neuropathology data also will be transferred, after Biostatistics Core quality control and validation, to the National Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA (U01 AG016976);(5) To undertake a developmental clinico-biomarker-neuropathologic study of HASD participants to determine the progression of biomarker changes in longitudinally assessed participants who transition from preclinical AD to symptomatic AD and who come to autopsy. Neuropathology will be the benchmark against which biomarker (CSF A?42 and pTau and PET-amyloid imaging) data will be assessed. With the Imaging and Biostatistics Cores and Projects 1 and 2, Core D will explore the contribution of AD biomarker changes with neuropathologic data including measures of A? and pTau burden, synaptic and neuronal loss.

Public Health Relevance

Core D: Neuropathology Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG003991-31A1
Application #
8739013
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Project Start
Project End
2019-04-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
31
Fiscal Year
2014
Total Cost
$176,162
Indirect Cost
$57,823
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Lucey, Brendan P; Mawuenyega, Kwasi G; Patterson, Bruce W et al. (2016) Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System. JAMA Neurol :
Esparza, Thomas J; Wildburger, Norelle C; Jiang, Hao et al. (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Sci Rep 6:38187
McKee, Ann C; Cairns, Nigel J; Dickson, Dennis W et al. (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 131:75-86
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Jin, Sheng Chih; Benitez, Bruno A; Deming, Yuetiva et al. (2016) Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. Methods Mol Biol 1303:299-314
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Van Schependom, Jeroen; Jain, Saurabh; Cambron, Melissa et al. (2016) Reliability of measuring regional callosal atrophy in neurodegenerative diseases. Neuroimage Clin 12:825-831
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-50
Su, Yi; Rubin, Brian B; McConathy, Jonathan et al. (2016) Impact of MR-Based Attenuation Correction on Neurologic PET Studies. J Nucl Med 57:913-7
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9

Showing the most recent 10 out of 756 publications